Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
15 participants
INTERVENTIONAL
2016-05-03
2016-05-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison Between iLux™ and LipiFlow® in the Treatment of Meibomian Gland Dysfunction
NCT03055832
iLux Treatment for Meibomian Gland Dysfunction (MGD)
NCT03055650
Effectiveness of Intense Pulsed Light for Improving Dry Eye Syndrome
NCT03396913
Effect of Thermal Pulsation System (Lipiflow) Treatment for Ocular Surface Disease Due to Meibomian Gland Dysfunction
NCT03843983
Intense Pulsed Light Study for Dry Eye Disease
NCT03089580
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
iLux 2020 System
Meibomian gland treatment (Day 0) according to instructions for use (IFU)/User Manual
iLux 2020 System
Medical device that applies localized heat and pressure therapy to the eyelid in order to express melted meibum from obstructed glands
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
iLux 2020 System
Medical device that applies localized heat and pressure therapy to the eyelid in order to express melted meibum from obstructed glands
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Active ocular infection
* Ocular surface abnormality; lid surface abnormalities
* Pregnant, nursing or not utilizing adequate birth control measures
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tear Film Innovations, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sr. CDMA Project Lead, CDMA Ocular Health
Role: STUDY_DIRECTOR
Alcon Research, LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
TearFilm Innovations Investigative Site
Encinitas, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.